MBX Biosciences, Inc. MBX 深 沪
已收盘 04-02 16:00:00 美东时间
32.99
+0.700
+2.17%
华盛通- 最 高33.70
- 今 开31.00
- 成交量 60.17万股
- 最 低 30.87
- 昨 收 32.29
- 总市值 15.67亿
- 52周最高 44.89
- 市盈率 静 --
- 换手率 1.27%
- 52周最低 6.81
- 委 比 71.92%
- 总股本 4751.02万
- 历史最高 44.89
- 量 比 1.53
- 振 幅 8.76%
- 历史最低 4.8069
- 每 手 1
- 风险率 10.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of $(0.47) per share from the
03-12 20:14
MBX Biosciences Announces End-of-Phase 2 FDA Meeting Results and Provides Phase 3 Development Plan For Canvuparatide
Based on feedback from the FDA, MBX plans to advance once-weekly canvuparatide into a Phase 3 trial in the third quarter of 2026.
03-09 20:09
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.
01-28 22:45
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
美股周涨跌榜 | 算力基建再提速！Galaxy Digital 涨超37%，获批电力容量翻番；创新药企IBRX大涨近137%
算力基建再提速！Galaxy Digital 周涨超37%，获批电力容量翻番；创新药企IBRX周涨近137%，在研创新药获批上市>>
01-17 10:31
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.
01-16 23:17
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
